ArticleBMC cancer2025
Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ondansetron oral soluble pellicles vs. azasetron for preventing nausea and vomiting in patients receiving antitumor therapies: a comparative observational study.Journal of cancer research and clinical oncology · 2026Observational
- Exploring Dacarbazine Complexation with a Cellobiose-Based Carrier: A Multimethod Theoretical, NMR, and Thermochemical Study.Molecules (Basel, Switzerland) · 2025Article
- Evaluating Theoretical Solvent Models for Thermodynamic and Structural Descriptions of Dacarbazine-Cyclodextrin Complexes. The Theoretical and Conductometric Study.Molecules (Basel, Switzerland) · 2025Article
- Optimal dosing regimen of ondansetron oral soluble pellicles for preventing postoperative nausea and vomiting after primary total joint arthroplasty: a randomized controlled clinical trial.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOndansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk.
methodsIn total, 163 patients with malignant tumours received 24 mg of ondansetron via orally soluble pellicles at 30 min before chemotherapy (8 mg each time for three consecutive administrations). The incidence rates of nausea and vomiting in the three days after chemotherapy were recorded.
resultsRegarding the effect of ondansetron on vomiting, the complete response (zero episodes of vomiting), major response (1-2 episodes of vomiting), minor response (3-5 episodes of vomiting), and failure (> 5 episodes of vomiting) rates were 96.9%, 1.2%, 1.2%, and 0%, respectively. The major efficacy rate for vomiting (complete response + major response rates) was 98.1%. Moreover, 96.3% of patients did not experience nausea, 2.5% of patients experienced mild nausea, 1.2% of patients experienced moderate nausea, and 0.0% of patients experienced severe nausea. The major efficacy rate for nausea (no nausea) was 96.3%. Age > 65 years was negatively associated with major efficacy for vomiting, and a chemotherapy regimen involving cisplatin was negatively associated with major efficacy for nausea. A total of 42 (25.8%) patients experienced adverse events. The most common adverse events were elevated levels of alanine transaminase (6.7%), elevated levels of aspartate transaminase (3.7%), fatigue (3.7%), and cough (2.5%).
conclusionOndansetron orally soluble pellicle shows good antiemetic efficacy and high safety in patients with malignant tumours who receive chemotherapy drugs with a moderate-to-high emetic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.